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Abstract
High-grade serous ovarian cancer (HGS-OvCA) is an aggressive form of epithelial ovarian cancer 
(EOC), and accounts for the majority of deaths due to EOC. The critical cellular processes and 
underlying molecular mechanisms that define this malignancy remain poorly understood. Using a 
syngeneic murine model, we investigated the changes that accompanied the progression to 
increased aggressiveness induced by in vivo passage of mouse EOC cells. We found that enhanced 
anoikis resistance was a key cellular process associated with greater aggressiveness and 
tumorigenicity in vivo. Biochemical studies revealed that the enhanced anoikis resistance was 
associated with the activation of the Src/Akt/Erk signaling pathway. A higher rate of metabolism 
and autophagy were also associated with increased anoikis resistance. Blocking these pathways 
with specific inhibitors and/or genetic modifications significantly increased anoikis in vitro and 
inhibited tumor development in vivo. In addition, we demonstrated that similar signaling pathways 
were also involved in a human EOC cell line model. Collectively, our data suggest that anoikis 
resistance represents a critical and a distinguishing feature underlying the aggressiveness of 
ovarian cancer cells.
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Introduction
Epithelial ovarian cancer (EOC) is the most deadly gynecologic disease. Over 70% of 
patients with EOC are diagnosed at advanced stages, characterized by massive ascites 
containing large numbers of tumor cells. These suspended tumor cells are shed from primary 
ovarian tumors and then attach and invade the mesothelium of the peritoneal wall and other 
organs, forming secondary lesions throughout the peritoneal cavity. At this stage the disease 
is very difficult to treat, and only temporary remission can be achieved with chemotherapy. 
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Patients commonly die of abdominal metastases; extra-abdominal metastasis is rare, a fact 
which reflects the unique behavior of EOC cells.
The gene signatures and main signaling pathways involved in EOC have been extensively 
investigated via high-throughput and integrated studies (1). However, identification of the 
oncogenic driver genes of EOC requires function-directed approaches. To search for 
relevant driver genes, we sought to examine the change in aggressiveness that results from 
in vivo passage of mouse EOC cells in a syngeneic mouse model. Compared to using human 
EOC cell lines in a xenograft model, this approach offered an immune-competent 
microenvironment-to yield more pathologically relevant findings.
The ID8 cell line was obtained through spontaneous transformation of normal ovarian 
surface epithelial cells from C57BL6 mice by repetitive passage in vitro. In vivo, 
intraperitoneally (i.p.)-injected ID8 cells produce tumors very similar to human HGS-OvCA, 
with similar oncogenic signaling pathways. Importantly, ID8 cells produce tumors in 
immune-intact mice, which allows the study of the tumor microenvironment and tumor-host 
interactions. The i.p.-injected ID8 cells preferentially metastasize to diaphragm, peritoneal 
wall, mesentery, and omentum (2–4).
We observed that daughter cells lines established from these tumors display increased 
aggressiveness upon re-injection into naïve mice, as defined by the time to onset of tumor/
ascites formation and morbidity in the mouse model. To identify the cellular processes that 
are critically involved in the increased aggressiveness observed in our model, we conducted 
function-directed cellular and biological analyses in vivo and in vitro. We compared the 
behavior and characteristics of the parent and daughter cell lines and then focused on the 
signaling pathways controlling the differences in cell functions to understand the molecular 
mechanisms underlying the increased aggressiveness of the daughter cells.
Results
In vivo passage of ID-8 cells resulted in greatly increased aggressiveness
Following i.p. injection of ID8-luc (ID8 cells expressing luciferase, termed ID8-P0) cells 
into C57BL6 mice, tumors and ascites developed in ~90 days. Tumor cells isolated from 
tumor nodules on the diaphragm (DP), peritoneal wall (PW), mesentery (MS), omentum 
(OM), liver (LV), kidney (KD), and floating cells in ascites were cultured in vitro. Their 
tumorigenic capacities were tested. All of these P1 cell lines displayed dramatically 
enhanced tumorigenic/metastatic potency. Time to tumor/ascites formation was reduced 
from 90 days to 22–45 days. In addition, the P1 cells obtained from different organs did not 
show significant differences in organ specificity. Regardless of where P1 cells were 
collected, they had similar preference to omentum when they were re-injected. Thus, we 
used PW-P1 (ID8-P1) cells as representative P1 cells for the most of the functional studies 
conducted in this work.
The mouse morbidity times were also changed: seven of 10 mice injected with ID8-P1 cells 
died at 21–24 days post injection, and all died by 28 days, while mice injected with ID8-P0 
cells died between 80–110 days post injection (Fig. 1A). The number of tumor metastases 
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on peritoneal organs increased dramatically in mice injected with ID8-P1 as compared with 
ID8-P0 cells (Fig. 1B, 1C). Thus, the ID8-P1 cell line represents a model of greatly 
increased aggressiveness, as compared with ID8-P0.
ID8-P1 cells exhibited enhanced anoikis resistance in vivo
To determine the differences between ID8-P0 and ID8-P1 tumors, we first did 
immunohistochemical (IHC) analyses on tumor sections. There were no significant 
differences in the expression of Ki67 (a cell proliferation marker, Fig. 2A), CD31 (vessel 
formation), or F4/80 (macrophage infiltration) staining between ID8-P0 andID8-P1 tumors 
(data not shown), suggesting that ID8-P1 cells did not gain increased proliferative or 
angiogenic abilities once the solid tumors were formed.
We postulated that the potently increased aggressiveness of ID8-P1 cells was related to early 
stage tumor cells survival and/or the ability of migration and invasion in the peritoneal 
cavity. To test these hypotheses, we first counted and compared living tumor cells 
(expressing GFP) by collecting peritoneal washings on selected days post-i.p. injection (n≥3 
mice per time point). As shown in Fig. 2B, there were approximately 50-fold more surviving 
ID8-P1 cells than ID8-P0 cells on days 5 and 10. The recovered living cells on day 5 were 
30% of the number of ID8-P1 cells injected (GFP-positive cells; ~1.5×106), compared to 
only about 0.6% (~3×104) of the injected ID8-P0 cell number at the same time point. The 
mice injected with ID8-P1 cells succumbed around 24 days post injection. In the mice 
injected with ID8-P0 cells, the number of peritoneal tumor cells increased from day 5 to day 
75, when solid tumors and/or ascites become evident. These data suggest that the ID8-P1 
cells have acquired an enhanced ability to resist anoikis after in vivo passage and that 
floating cell survival in peritoneal cavity after i.p. injection, which mimics early stage tumor 
cell dissemination of EOC, is critical for aggressiveness of tumor progression.
To compare the ability to attach and invade peritoneal organ sites, we examined tumor 
metastases on omentum, diaphragm, peritoneal wall, liver, kidney, intestine, and adipose 
tissue for GFP fluorescence under a dissecting microscope. We found that the omentum was 
the favored tissue for metastasis for both ID8-P0 and ID8-P1 cells. The omentum showed 
GFP fluorescence (derived from tumor cells) above background at 1 day post injection, 
when there was no detectable fluorescence in other organs (Fig.2C and 2D and data not 
shown). However, the attachment and/or invasion of tumor cells to omentum were not 
significantly different between ID8-P0 and ID8-P1 cells in the first 10 days post injection, 
suggesting that ID8-P1 cells did not acquire stronger cell adhesion and/or invasion ability at 
an early stage, and that the higher number of surviving floating tumor cells are likely to 
account for the early onset of solid tumor development.
ID8-P1 cells were more resistant to anoikis in vitro
Anoikis assays in low attachment poly-HEMA coated plates were used to test cell survival 
in a suspended condition (5). After 3 days in serum free (SF) medium, ~40% of ID8-P1 
cells, but ≤5% of ID8-P0 cells survived (Fig. 3A). After 3 days in 5% FBS, about 75% of 
ID8-P1 and 25% of ID8-P0 cells survived, respectively (Fig. 3B). Anoikis resistance is 
necessary for anchorage independent growth (6). Colony formation was 4-fold greater for 
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ID8-P1 cells than for ID8-P0 cells (101 ± 5 vs. 23 ± 3, Fig. 3C). Reduced apoptosis in ID8-
P1 cells as compared to ID8-P0 cells was supported by reduced activation of caspase-3, as 
detected in a Western blot for cleaved caspase-3 (Fig. 3D). This difference could be detected 
only in suspended cells. No caspase-3 activation (cleavage) was detected in either ID8-P0 or 
ID8-P1 when cells were attached (Fig. 3D). Interestingly, when cells were cultured in 
standard 2D cell culture dishes, no significant difference in cell proliferation was observed 
between ID8-P0 and ID8–P1 cells using MTT assays, but ID8-P1 cells had a tendency to 
have lower cell numbers (Fig. 3E). Flow cytometric analyses of cell cycles were also used to 
investigate whether there was a difference between ID8-P0 and ID8-P1 in cell cycle 
progression cultured in 2D cell culture dishes. The percentages of ID8-P0 cells in G1, S, and 
G2\M stages were 46.5±1.5%, 9.2±1.1%, and 34.5±1.1%, respectively. The percentages of 
ID8-P1 cells in G1, S, and G2\M stages were 50.3±2.3%, 11.6±1.4%, and 28.5±3.2%, 
respectively (Fig. 3G). These differences are not statistically significant. These results are 
consistent to our in vivo Ki67 staining data, supporting that ID8-P1 cells did not have 
increased proliferative capacity when cells were associated with matrix. We also compared 
cell migration using Boyden chamber transwell assays and found no significant difference 
between P0 and P1 cells (Fig. 3E). These results were consistent with our observations in 
mice that increased attachment of ID8-P1 cells to peritoneal organs at an early stage was not 
observed. Together, these results suggest that increased anoikis resistance was likely to be 
the most relevant and important feature acquired by ID8-P1 cells after in vivo passaging.
Src/Akt/Erk signaling was necessary and sufficient for increased anoikis resistance
To elucidate the molecular mechanisms by which ID8-P1 cells gained anoikis resistance, we 
examined survival signaling pathways. Src/Akt/Erk signaling is a key mediator of cell 
survival (7). Western blot analyses showed that when cells were grown under adherent 
conditions, there were no obvious differences in activated (phosphorylated) Src, Akt, or Erk 
between ID8-P0 and ID8-P1 cells (Fig. 4A). However, when cells were grown under 
suspended conditions, Src, Akt, and Erk were highly activated in ID8-P1 cells, as compared 
to ID8-P0 cells, in the absence or presence of FBS (Fig. 4A).
To show that these molecules were functionally involved in anoikis, we used siRNA (for 
Src) and/or selective inhibitors (PP2 for Src; MK2206 for Akt; and PD98059 for Erk). All 
reduced the cell survival rate when ID8-P1 cells were cultured in suspension (Fig. 4B). 
These inhibitors also significantly reduced the colony forming ability of ID8-P1 cells (Fig. 
4C). In vivo, PP2 reduced the number of surviving ID8-P1 cells in the mouse peritoneal 
cavity at day 5 post injection from ~ 1.5 million to ~ 0.08 million, a level similar to that seen 
for ID8-P0 cells. These data strongly suggest that enhanced Src activation is a crucial factor 
in the aggressiveness of ID8-P1 cells (Fig. 4D).
We further tested the involvement of Src in anoikis resistance by the overexpression of 
constitutively active Src (CA-Src) in ID8-P0 cells. The increased pSrc level in ID8-P0 cells 
was verified by Western blot analysis (Fig. 4E). Colony formation and anoikis assays 
showed that overexpression of CA-Src in ID8-P0 increased anchorage independent growth 
and cell survival in suspension (Fig. 4F, G). In addition, increased Src signaling led to more 
surviving floating ID8-P0 cells in the mouse peritoneal cavity at day 5 post injection (Fig. 
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4H). Therefore, Src signaling appeared to be necessary and sufficient for increased anoikis 
resistance in ID8 cells both in vitro and in vivo.
Metabolism and autophagy were important for anoikis resistance in ID8-P1 cells
Cells can be rescued from anoikis by enhanced metabolism, which is regulated by Akt 
signaling (8). We tested whether increased anoikis resistance in ID8-P1 cells was related to 
changes in cellular metabolism. The ATP level was substantially higher in ID8-P1 cells, as 
compared to that of ID8-P0 cells (Fig. 5A). Consistently, ID8-P1 cells consumed 2-fold 
more glucose than ID8-P0 cells (3.9±0.3 mmol vs. 1.5±0.2 mmol; Fig. 5B). In addition, 
ID8-P1 cells produced more lactate than ID8-P0 cells in culture medium (Fig. 5C). Besides 
mitochondrial oxidative phosphorylation pathway, cancer cells have adapted to derive a 
significant amount of their ATP from converting glucose to lactate, a process termed the 
Warburg effect (9). We checked whether the increased metabolic rate in ID8-P1 cells was 
dependent on the mitochondrial pathway or glycolysis by using mitochondrial complex 1 
inhibitor rotenone, glycolysis inhibitor 2-deoxyglucose (2DG) and lactate dehydrogenase A 
(LDHA) inhibitor oxamate (8, 10). As shown in Fig.5A and 5C, blocking of mitochondrial 
pathway and glycolysis both significantly decreased the ATP level and lactate secretion in 
ID8-P1 cells, indicating ID8-P1 cells used both pathways to maintain a high metabolic rate.
To explore the functional importance of enhanced metabolism in ID8-P1 cells, we cultured 
both ID8-P0 and ID8-P1 in glucose-free medium in low attachment plates. As shown in Fig. 
5D, the survival rate of ID8-P1 cells decreased dramatically in glucose-free medium, while 
the survival rate of ID8-P0 cells was only slightly affected, indicating that the anoikis 
resistance of ID8-P1 cells was glucose-dependent. Glucose is transported from extracellular 
spaces into cells by glucose transporters, and mainly via Glut-1 in cancer cells. Western blot 
analyses showed that the Glut-1 level was elevated in ID8-P1 as compared to ID8-P0 cells 
(Fig. 5E). Ectopic expression of CA-Src in ID8-P0 cells increased Glut-1 expression in these 
cells, suggesting Src is an important regulator of Glut-1 (Fig 5E).
Given the important role of autophagy in tumor cell metabolism and enhanced energy 
production, we examined the levels of LC3B (a marker of autophagy) in ID8-P1 cells. 
Indeed, LC3B was greatly elevated in ID8-P1 cells (Fig. 6A). To test the functional 
importance of the autophagic pathway, the effects of selective inhibitors chloroquine (CQ) 
and baf A1 on the survival rate of suspended cells were tested. ID8-P1 cell survival was 
reduced from 43% to 5% and colony formation in soft agar dropped from 90±7 to 50±5 
(Fig. 6B, C). Injection of CQ (i.p.) also efficiently inhibited ID8-P1 tumor cell survival in 
the mouse peritoneal cavity on day 5 post injection (Fig. 6D).
ID8-P1 cells from other organs showed similar characteristics as ID8-P1 from the 
peritoneal wall (PW)
Similar to ID8-P1 cells form PW, the additional P1 cell lines (ID8-DP-P1, ID8-OM-P1, and 
ID8-floating-P1) had no significant changes in cell proliferation (analyzed in attached 2D 
tissue culture plates using MTT assays, Fig. 7A), migration (Fig. 7B), and invasion (Fig. 
7C), when compared to those of P0 cells. In contrast, all of these P1 cell lines displayed 
enhanced survival when cells were cultured in suspension (Fig. 7D), suggesting that anoikis 
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resistance is a common feature of P1 cells, regardless their organ sites. In addition, up-
regulations of Src, Glut-1, and LC3B expression in all three P1 cell lines, compared to P0 
cells, are shown in Figs. 7E to 7G.
Src-mediated anoikis resistance in in vivo passaged human EOC cells
To test whether anoikis resistance is also an important feature of aggressiveness in a similar 
model using human EOC cells, we compared the cell lines SKOV3 and SKOV3ip1. 
SKOV3ip1 cells were developed by Dr. Mien-chie Hung’s lab through in vivo passage of 
SKOV3 cells in nu/nu mice. As reported by others, SKOV3ip1 cells showed increased 
aggressiveness upon re-injection into naïve nu/nu mice, as compared with the parent 
SKOV3 cells (11). Similar to mouse ID8-P1 cells, SKOV3ip1 cells were much more anoikis 
resistant than SKOV3 cells (survival rate: 64% vs. 30%, Fig. 8A). In the anchorage-
independent growth assay, SKOV3ip1 formed two-fold more colonies than SKOV3 (31±4 
vs. 13±3, Fig. 8B). More importantly, when these cells were i.p. injected into NOD/SCID 
mice (5 × 106 cells per mouse, n=3), only 2±1 ×104 SKOV3 cells, as compared with 5.6±0.5 
× 105 SKOV3ip1 cells (a 28-fold difference), survived 5 days post injection in the mouse 
peritoneal cavities (Fig. 8C). Finally, Src signaling was activated in suspended SKOV3ip1 
cells, but not in suspended SKOV3 cells (Fig. 8D).
We also tested pSrc expression in another pair of human in vivo passaged cell lines: HEY 
and HEY1B. HEY1B was developed through in vivo passage of HEY cells (12). Western 
blot analyses showed that Src was highly activated in HEY1B cells (Fig. 8E) and HEY1B 
cells were much more resistant to anoikis than HEY cells in serum-free medium (Fig. 8F). 
To further verify Src-mediated anoikis resistance in human ovarian cancer cell lines, we 
overexpressed constitutive Src (CA-Src) in OVCAR5 and OVCA 420 cells (Fig. 8E). As 
shown in Fig. 8G, H, overexpression of CA-Src in these cells significantly improved their 
survival percentages in suspension condition.
Discussion
More than one third of ovarian cancer patients present with ascites at diagnosis, and almost 
all have ascites at recurrence. The presence of ascites correlates with the peritoneal spread of 
ovarian cancer and is associated with poor disease prognosis (13). It is well-known that 
ascites contains large number of tumor cells and in fact, most of the established human EOC 
cells lines were isolated from ascites, with only a few from solid tumors. However, to our 
knowledge, the potential correlation and functional relationship between the numbers of 
floating peritoneal tumor cells and their cellular properties to disease prognosis have not 
been studied. Using mouse EOC syngeneic cell pairs generated via in vivo passaging, we 
found that enhanced anoikis resistance is a critical cellular process that correlates to tumor 
aggressiveness judged by time to tumor/ascites onset and morbidity. This notion is strongly 
supported by both in vivo and in vitro studies.
We have examined the peritoneal tumor cells survival at early stage post injection, which 
recapitulates early stage dissemination of EOC cells. It is highly significant and interesting 
to find that the numbers of survival floating cells are best correlated with tumor 
aggressiveness. This suggests that removing ascites from EOC patients is not only for 
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reduction of patients’ discomfort and burden, but also more importantly for reduction of the 
important source for solid tumor/metastases development. It also suggests that in addition to 
optimal debunking solid tumors, more complete washings to remove loosely attached or 
floating tumor cells in the peritoneal cavity may have clinical benefit for patients. 
Technically, the early stage floating cell counting may represent an alternative and more 
convenient method for analyze tumorigenesis in i.p. EOC models in vivo, when compared to 
the longer-time solid tumor end point method, which needs to be tested in more human 
and/or mouse EOC cells.
Src activation is one of the most extensively characterized oncogenic signaling pathways. It 
controls many cellular processes including survival. During the course of the current study, 
when we had already generated our ID8-P1 cell lines and independently found that Src is 
constitutively activated in ID8-P1 cells, Ward et al., using a similar approaches, reported 
that elevated FAK and c-Src tyrosine kinase activation are associated with ID8-IP cells 
when compared to parental ID8 cells (14). However, their ID8-IP cells were derived from 
ascites by expansion of ascites cells after culturing under anchorage-independent conditions 
on low binding poly-HEMA coated plates for 3–4 weeks (14). In contrast, we isolated P1 
cells from solid metastases on different organs. In addition, our isolated tumor cells were 
selected for transfected GFP using antibiotics, and were free of host cell contamination. The 
original ID8 cells were obtained through spontaneous transformation of normal ovarian 
surface epithelial cells from C57BL6 mice by repetitive passage in vitro. Additional 
passages of ID8 cells in vitro in our lab did not change their tumorigenic potential, with 
tumor/ascites formation requiring 80–110 days in the over 100 mice tested. In contrast, only 
one round of in vivo passaging dramatically altered the aggressiveness of these cells, 
indicating that the tumor microenvironment and host cells play important roles in 
modulating tumor cell properties. Which host cells and/or other tumor microenvironmental 
factors play pivotal roles in these interactions and modifications remains to be further 
investigated. It is also possible that in vivo passaging effectively select highly anoikis 
resistant cells.
While the previous work by Ward et al. focused on FAK (14), we show here that Src is not 
only necessary, but also sufficient to induce anoikis resistance in EOC cells. We found that 
in vitro anoikis and colony formation assays, but not proliferation in 2D growth assays, are 
highly consistent with in vivo early stage peritoneal cell survival assays in all of our 
functional studies, suggesting these in vitro assays recapitulate the anoikis resistance 
properties of tumor cells in vivo. We further show that ID8-P1 cells have increased glucose 
metabolism and ATP production, related to their increased Glut-1 expression, which is 
likely to be regulated in part by Src activation. Increased metabolism is functionally 
involved in anoikis resistance. Moreover, ID8-P1 cells display up-regulation of several 
autophagic factors, which also functionally contribute to anoikis resistance.
The mouse EOC cell model has the advantage of being an immune-competent model, better 
representing the natural state. The potential utility of the ID8 cell/C57BL6 mouse model in 
human disease was demonstrated by our experiments with the human SKOV3/SKOV3ip1, 
and HEY/HEY1B pairs, which displayed similar oncogenic alternations in signaling 
pathways for anoikis resistance and Src activation.
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Taken together, our studies have provided strong evidence that the level of anoikis 
resistance of EOC cells may be a good indicator of tumor aggressiveness in vivo, which may 
be conveniently analyzed at early stage of tumor i.p. injection, or even using one of the in 
vitro anchorage-independence assays. This notion needs to be tested further in more EOC 
cells and models. More importantly, this is the first study showing that the anoikis resistance 
in EOC cells is likely to be a key driving process that controls disease progression and 
prognosis. Removing or eradicating floating tumor cells more completely, in addition to 
solid tumors, may have clinical benefits to EOC patients.
Materials and Methods
Materials
The following reagents were used: PP2 (Tocris bioscience, Minneapolis, MN), MK2206 
(Biovision, Milpitas, CA), PD98059 (Enzo Life Sciences, Farmingdale, NY), Chloroquine 
(CQ) (Sigma, St. Louis, MO), Bafilomycin A1 (baf A1) (Sigma, St. Louis, MO), Src siRNA 
(Dharmacon, Pittsburgh PA), Rotenone (Sigma, St. Louis, MO), 2-deoxyglucose (Sigma, St. 
Louis, MO), sodium oxamate (Sigma, St. Louis, MO). Antibodies against pSrc, pAkt, pErk, 
LC3B, and cleaved caspase3 were from Cell Signaling (Boston, MA). Antibodies against 
Glut-1, CD31, Ki-67, and F4/80 were from Millipore (Billerica, MA), Abcam (Cambridge, 
MA), Ebioscience (San Diego, CA), and BIO-RAD (Hercules, CA), respectively.
Cell lines, culture, and mouse model
ID8 cells were obtained from Dr. Paul F. Terranova (University of Kansas Medical Center). 
Cells were cultured in DMEM supplemented with 4% fetal bovine serum, 100 units/mL 
penicillin, 100 µg/mL streptomycin, 5 µg/mL insulin, 5 µg/mL transferrin, and 5 ng/mL 
sodium selenite. The ID8-luc cell line (expressing both GFP and luciferase) was established 
as described (15). SKOV3 and SKOV3ip1 (courtesy of Dr. Mien-Chie Hung, University of 
Texas M. D. Anderson Cancer Center) were cultured in DMEM/F12 supplemented with 4% 
fetal bovine serum. ID8-luccells (5 × 106) were injected into the peritoneal cavity ofC57BL6 
mice. Between 80 and85 days post injection, tumor nodules on the peritoneal wall were 
isolated and cultured with Zeocin (100 µg/mL) selection to exclude non-tumor cells. The 
new cell lines weretermedID8-P1. All animal experiments were done under the protocols 
approved by Indiana University Animal Care and Use Committee.
Cell cycle analysis by flow cytometry
ID8-P0 and P1 cells cultured in complete medium were collected, washed 2 times in PBS 
and fixed in 75% ice-cold ethanol for 2 hours. Cells were stained in 500 µl Propidium Iodide 
(PI) staining solution: 0.1% (v/v) Triton X-100 in PBS with 100 µg DNAse-free RNAse A 
and 20 µl 500 µg/ml PI at 37°C for 15 minutes. Data acquisition was performed using a BD 
LSRII flow cytometer and analyzed by the FlowJo software (Tree Star, Inc. Ashland, OR, 
USA).
Anoikis assays
Cells (5 × 105) were plated onto poly-HEMA coated 6-well plates (Corning) in growth 
medium to prohibit attachment. After 24, 48, and 72 hours in suspension, cells were 
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transferred onto regular cell culture plates in growth medium supplemented with FBS (1%) 
to aid attachment. After 4 hours, attached cells were trypsinized and counted using a 
hemocytometer. Experiments were repeated three times.
Cell survival in mouse peritoneal cavity
ID8-P0 or ID8-P1 cells (5 × 106) were i.p. injected into C57BL6 mice (n=3 per group). At 
several time points post injection, mice were sacrificed and the peritoneal cavities were 
washed with 3 mL DMEM medium. The free floating tumor cells inthe wash medium were 
counted with a hemocytometer under a fluorescent microscope (SMZ1000, Nikon, Melville, 
NY). Dead cells were excluded by trypan blue staining.
Soft agar colony assays
Cells were suspended in 0.35% agar and seeded onto a 0.5% agar layer in 24-well plates (5 
× 103 cells per well) in triplicate. Two weeks later, cells were stained with crystal violet. 
Three fields per well were imaged and colonies were counted.
Measurement of ATP level, glucose uptake and lactate secretion
ID8-P0 and ID8-P1 cells were seeded into poly-HEMA-coated 24-well plates and cultured 
in 1 mL DMEM with 25 mM glucose for 24 hours. Then cells and the culture medium were 
separated by centrifugation. Cell number was counted and cells were used to check ATP 
level by CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI). The 
culture medium was used to check glucose level by Amplex® Red Glucose assay kit (Life 
technologies, NY) and lactate level by Lactate assay kit (Abcam, MA). All of these results 
were normalized by cell number. The fold changes were calculated by dividing the 
normalized values of ID8-P1 cells by the normalized values of ID8-P0 cells. Experiments 
were repeated three times.
Western blot
Western blot analyses were conducted using standard procedures and proteins were detected 
using primary antibodies and fluorescent secondary antibodies (Li-Cor Biosciences, Lincoln, 
NE). The fluorescent signals were captured on an Odyssey Infrared Imaging System (Li-Cor 
Biosciences, Lincoln, NE).
Statistical Analyses
Data are presented as mean ± SD. For differences between two groups the Students t-test 
was employed. The statistical program GraphPad Prism 5, Ver. 5.04 (GraphPad Software, 
Inc., La Jolla, CA) was used for all analyses. The significance level was set at P< 0.05.
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Figure 1. ID8-P1 cells were more aggressive than ID8-P0 cells in vivo
A. Kaplan-Meier survival curves of mice i.p. injected with ID8-P0 or ID8-P1 cells (n=10 per 
group). B. Representative images of tumors on the peritoneal wall and diaphragm of the 
mice injected with ID8-P0 or ID8-P1 cells on the indicated days post-injection (dpi). C. The 
average numbers of tumor nodules on the peritoneal wall and diaphragm in mice injected 
with ID8-P0 or ID8-P1 cells. *** P<0.001.
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Figure 2. ID8-P1 cells survived longer than ID8-P0 cells in the mouse peritoneal cavity
5×106 ID8-P0 or ID8-P1 cells were i.p. injected into C57BL6 mice. At designated time 
points after injection, mice were sacrificed. A. Representative images of Ki67 staining of 
ID8-P0 and ID8-P1 tumors. B. Fluorescent tumor cells in peritoneal washes were counted 
(n=3 per time point per group). C. Fluorescent tumor cells that attached to peritoneal organs 
were detected (n=3 per time point per group). Representative images of tumor metastases on 
omentum of the mice 5 days after injection. D. Representative images of tumor metastasis 
on the peritoneal wall of the mice 5 days after injection.
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Figure 3. ID8-P1 displayed enhanced anoikis resistance in vitro
A–B. Survival of ID8-P0 and ID8-P1 cells under suspended conditions with or without FBS 
(SF: serum free; FBS 5%). C. Colony numbers of ID8-P0 and ID8-P1 cells in soft agar. D. 
Western blot analysis showing cleaved caspase-3 levels in ID8-P0 and ID8-P1 cells under 
different culture conditions. E. Migration of ID8-P0 and ID8-P1 cells through Transwell 
membranes coated with collagen I (Col I), vitronectin (VN), or fibronectin (FN). F. 
Proliferation of ID8-P0 and ID8-P1 cells on plastic plates over 3 days with FBS (5%). G. 
Flow cytometric analyses of ID8-P0 and ID8-P1 cell cycles. Representative results are 
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shown in the left panels and the summary of 3 repeated experiments is shown in the right 
panel. *** P<0.001.
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Figure 4. Src/Akt/Erk signaling was constitutively activated and functionally involved in anoikis 
resistance in ID8-P1 cells
A. pSrc, pAkt, pErk levels in ID8-P0 and ID8-P1 cells under different culture conditions by 
Western blot analyses. B. Survival of ID8-P1 cells under suspended conditions treated with 
Src siRNA (100 µM) and selective inhibitors: PP2 (10 µM), MK2206 (1 µM), PD98059 (30 
µM). C. Quantification of soft agar colony numbers of ID8-P1 cells treated with inhibitors. 
D. Number of floating ID8-P1 cells in mouse peritoneal cavities treated with the Src 
selective inhibitor PP2 (daily i.p. injection at a dose of 2 mg/kg, n=3). E–G. Ectopic 
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expression of CA-Src in ID8-P0 increased anoikis resistance. E. pSrc levels in ID8-P0 and 
ID8-P0-CA-Src cells by Western blot analyses. F. Anoikis assays of ID8-P0 and ID8-P0-
CA-Src cells in SF medium. G. Colony formation of ID8-P0 and ID8-P0-CA-Src cells in 
soft agar. H. Numbers of floating ID8-P0 and ID8-P0-CA-Src cells in mouse peritoneal 
cavities. * P<0.05; **, P< 0.01; *** P<0.001.
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Figure 5. Enhanced metabolism was important for anoikis resistance in ID8-P1 cells
A–C, ID8-P0 and ID8-P1 cells were cultured in 1 mL DMEM with 25 mM glucose with or 
without an inhibitor [(rotenone (5 µM), 2-deoxyglucose (2DG) (10 mM), or oxamate (20 
mM)] for 24 hours. Cells and culture medium were separated by centrifugation and cell 
number was counted. Results are normalized by cell number. A. Comparison of ATP levels 
of suspended ID8-P0 and ID8-P1 cells. B. Glucose consumption of suspended ID8-P0 and 
ID8-P1 cells over 24 hours. C. Comparison of lactate secretion of ID8-P0 and ID8-P1 cells. 
D. Survival of ID8-P0 and ID8-P1 cells in glucose-free medium and 25 mM glucose 
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medium. E. Glut1 level in ID8-P0, ID8-P1 and ID8-P0; CA-Src cells by Western blot. *** 
P<0.001.
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Figure 6. Increase of autophagy protected ID8-P1 cells from anoikis
A. Expression of LC3B in ID8-P0 and ID8-P1 cells by Western blot analyses. B. 
Quantification of soft agar colony numbers of ID8-P1 cells treated with CQ (30 µM) and baf 
A1 (5 µM). C. Survival of ID8-P1 cells under suspended conditions treated with selective 
autophagy inhibitors: CQ (30 µM) and baf A1 (5 µM). D. Numbers of floating ID8-P1 cells 
when treated with selective autophagy inhibitor CQ (daily i.p. injection at a dose of 50 
mg/kg, n=3) in mouse peritoneal cavities. * P<0.05; **, P< 0.01; *** P<0.001.
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Figure 7. Characterization of ID8-P1 cells from other organ sites
A. Cell proliferation of ID8-P0, ID8-DP-P1, ID8-OM-P1, and ID8-floating-P1 cells on 2D 
cell culture plates over 3 days in the presence of FBS (5%) analyzed by MTT assays. B. Cell 
migration of ID8-P0, ID8-DP-P1, ID8-OM-P1, and ID8-floating-P1 cells through Transwell 
membranes coated with collagen I (Col I). C. Cell invasion of ID8-P0, ID8-DP-P1, ID8-
OM-P1, and ID8-floating-P1 cells through Transwell membranes coated Matrigel. D. Cell 
survival of ID8-P0, ID8-DP-P1, ID8-OM-P1, and ID8-floating-P1 cells under suspended 
conditions in serum-free medium. E–G. Expression levels of pSrc, Glut1, and LC3B in ID8-
P0, ID8-DP-P1, ID8-OM-P1 and ID8-floating -P1 cells by Western blot analyses.
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Figure 8. Increased anoikis and Src activation in SKOV3ip1 cells
A. Survival of SKOV3 and SKOV3ip1 in the anoikis assay. B. Colony numbers of SKOV3 
and SKOV3IP1 grown in soft agar. C. Numbers of floating living tumor cells recovered in 
washes of NOD/SCID mouse peritoneal cavities (n=3). D. pSrc levels in SKOV3 and 
SKOV3ip1 cells analyzed by Western blot. E. pSrc levels in HEY, HEY1B, OVCAR5, 
OVCA420, and their CA-Src overexpression cells by Western blot analyses. F. Anoikis 
assays of HEY and HEY1B cells in SF medium. G. Anoikis assays of OVCAR5 and 
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OVCAR5, CA-Src cells in SF medium. H. Anoikis assays of OVCA 420 and OVCA 420, 
CA-Src cells in SF medium. * P<0.05; **, P< 0.01; *** P<0.001.
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